BD4QoL: Big Data for Quality of Life in Head and Neck Cancer

Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Other)
Overall Status
Recruiting
CT.gov ID
NCT05315570
Collaborator
Fondazione Casa Sollievo della Sofferenza (Other), University Hospital Birmingham NHS Foundation Trust (Other), Dotsoft Olokliromenes Efarmoges Diadiktioy kai Vaseon Dedomenon AE (Other), IBM Ireland limited (Other), INETUM (Other), Multimed Engineers srl (Other), Regione Lombardia (Other), Universidad de la Iglesia de Deusto Entidad Religiosa (Other), Universidad Politecnica de Madrid (Other), University of Milan (Other), Universitetet i Oslo (Other), Johannes Gutenberg University Mainz (Other), Aria S.p.A. (Other), University of Bristol (Other)
420
Enrollment
3
Locations
2
Arms
39.1
Anticipated Duration (Months)
140
Patients Per Site
3.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Depending on disease stage, head and neck cancer (HNC) can be cured either with a single modality or with multimodal treatments, consisting of various combinations of surgery, radiotherapy, and chemotherapy. Despite treatment with curative intent, loco-regional recurrences and/or distant relapses are frequent. Moreover, these therapeutic approaches result in significant acute toxicities and late sequelae. Therefore, quality of life (QoL) is often impaired in these survivors. It is known that QoL is a prognostic factor because it is related to overall survival in cancer patients and to loco-regional control in HNC patients.

The adoption of mobile technologies of common use (i.e. embedded into standard mobile phones) for behavior reconstruction and linkage of behavior modifications to quality of life indicators, and the realization of predictive models for quality of life modifications will allow seamless and unobtrusive data capture over time, making the execution of clinical investigations more precise and less burdensome as compared to standard (manual) data capture.

The main aim of the present study is to reduce and to anticipate, with the use of the non-invasive Big data for quality of life (BD4QoL) platform, the proportion of HNC survivors experiencing a clinically meaningful reduction in QoL.

Condition or DiseaseIntervention/TreatmentPhase
  • Other: BD4QoL platform
Phase 3

Detailed Description

The BD4QoL platform consists of a set of services to allow patient monitoring and empowerment, through two main tools: Point of Care application to manage all patients data and follow-up by clinical investigators, and a mobile application (App) installed on participating subject's smartphone. Also, a web-form tool is delivered to allow the QoL questionnaire completion.

To achieve the study objectives, the BD4QoL platform will use the following sensors embedded in a smartphone to collect data which will be used to identify behavioral and affective traits associated with study outcomes. Sensors at mobile phone used to collect relevant data are the following:

  • Accelerometer (x,y,z measurements)

  • Global Positioning System - GPS (Lat, Long)

  • Ambient light (measurement of light in the room / area where the mobile device is located)

  • Screen (Status ON or OFF for smartphone device screen)

  • Activity (type of activity with which the person engages,which can be one of these: Still, Walking, Running, On_Bicycle, In_Vehicle)

  • Steps (total number of steps per day and per hour)

  • Daily connections to wifi networks (naming of wifi connections as well as corresponding duration)

  • Data detected from the mobile device's operating system (phone usage logs, phone applications usage) and from external datasets (steps, identification of places (Points of Interest) visited based on participant's permissions, through the correlation of one's GPS signal with external datasets from Foursquare and OpenStreet maps) The above data will be used to detect activities and behaviors which have a high likelihood of being meaningfully related with participants' QoL trajectories.

The BD4QoL App, available for Android, will be able to collect and store data about the following domains: mobility, physical activity, activities of daily living, instrumental activities of daily living, socialization, cognitive function, health related activities as well as affective personal data. A summary of the findings and the supporting data will be available to the patient and clinical investigators , through a dashboard available on mobile devices for patients and through the Point of Care (PoC) web tool for clinical investigators. The data collected by the mobile App will not be available to the technology manufacturer and will be transferred in almost-real-time (real-time when possible, as soon as data transfer is available) to the central BD4QoL repository (as long as there is available storage in the local memory storage of the mobile device).

In the interval between visits, study participants, allocated in the intervention arm, will be able to interact electronically with a chatbot, which will be part of the BD4QoL platform, implementation based on IBM Watson technology. The chatbot is an application to empower patients to manage their QoL and health, under the supervision of clinical investigators. The chatbot will have a series of e-coaching (electronic coaching) functions that include: (i) dialogue management that allows the patient to be counselled by chatting electronically in a structured and effective way; (ii) management of two-way communications with healthcare professionals [e.g. for the patient to request specific support in case of special needs, or for the chatbot to invite the patient for a visit in case of an early detection of health-related QoL (HRQoL) or health issues; identified people will have to be listed on the delegation log by the Principal Investigator (PI)]; (iii) detection of affective traits embodied in the e-coach / patient dialogue, through sentiment analysis and emotion analysis technologies to gather data about the participant mood. The latter element can be used to both re-adapt the chatbot counselling strategy, as well as to provide additional information on subjects mood to clinical investigators. The adverse events that the chatbot will be able to recognise will be the following: fatigue, malaise, fever, excessive sleepiness, difficulty sleeping, depression, change in social circumstances, neck swelling, facial pain, difficulty breathing, nose bleeds, difficulty speaking, dry mouth, tooth loss, muscle weakness, ear pain, difficulty hearing, tinnitus, vertigo, nausea, diarrhea, constipation, difficulty seeing, dry eye, eye pain, nervous eyelid, eye floaters, swollen eye, bleeding eyes, eye watering, sexuality issues, weight loss, difficulty swallowing, mouth sores, appetite loss, difficulty opening mouth, difficulty eating, increased sensitivity to smells, no taste.

The platform will provide the investigators with real time data of device usage (e.g number and type of alerts and chatbot interactions by patients) and it will integrate the electronic case report forms (eCRFs) as a study monitoring dashboard.

The BD4QoL platform used in this trial is not to be considered a medical device and is used for experimental assessment only. No drugs will be suggested by the automated chatbot responses. Tips provided by the chatbot regarding detected symptoms are also not to be considered clinical advice by any means and should not be a substitute for conversations with a member of a trained medical personnel.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
420 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Multicenter, international, randomized (2:1 ratio), open-label, superiority trialMulticenter, international, randomized (2:1 ratio), open-label, superiority trial
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
A Multicenter Randomized Trial for Quality of Life Evaluation by Non-invasive Intelligent Tools During Post-curative Treatment Follow-up for Head and Neck Cancer
Actual Study Start Date :
Mar 28, 2022
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jul 1, 2025

Arms and Interventions

ArmIntervention/Treatment
Experimental: Intervention arm

Study participants will be followed up as per clinical practice and will receive the investigational electronic platform, including an Android-based app. Study subjects will be asked to fill in questionnaires at study entry and during follow-up.

Other: BD4QoL platform
The BD4QoL platform consists of a set of services to allow patient monitoring and empowerment, through two main tools: Point of Care application to manage all patients data and follow-up by clinical investigators, and a mobile application (App) installed on participating subject's smartphone. Also, a web-form tool is delivered to allow the QoL questionnaire completion.

No Intervention: Control arm

No specific mobile apps will be provided to study participants, who will be followed as per clinical practice. Study subjects will be asked to fill in questionnaires at study entry and during follow-up.

Outcome Measures

Primary Outcome Measures

  1. Clinically meaningful deterioration of global QoL between at least 2 visits during post-treatment follow-up [6-24 months]

    Proportion of HNC survivors experiencing a clinically meaningful global health-related EORTC QLQ-C30 QoL deterioration (decrease ≥10 points)

Secondary Outcome Measures

  1. Time to the first clinically meaningful deterioration of global QoL between at least 2 visits during post-treatment follow-up [6-24 months]

    Time to first clinically relevant deterioration of EORTC QLQ-C30 global score (decrease ≥10 points)

  2. Clinically meaningful deterioration of pre-specified EORTC-QLQ-C30 scales QoL between at least 2 visits during post-treatment follow-up [6-24 months]

    Pre-specified C30 scales (emotional functioning, role functioning, insomnia). Score range: 0-100 (higher score = higher/healthier level of functioning for emotional and role functioning; higher score = higher level of symptomatology / problems for insomnia)

  3. Clinically meaningful deterioration of pre-specified EORTC-QLQ-HN43 scales QoL between at least 2 visits during post-treatment follow-up [6-24 months]

    Pre-specified HN43 scales (swallowing, teeth, opening mouth, speech problems, trouble with social eating, fear of progression, emotional functioning, fatigue). Score range: 0-100 (higher score = higher/healthier level of functioning for emotional functioning; higher score = higher level of symptomatology / problems for the remaining specified scales)

  4. Clinically meaningful deterioration of pre-specified EQ-5D-5L domains between at least 2 visits during post-treatment follow-up [6-24 months]

    EQ-5D-5L domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). For each dimension, levels of perceived problems are coded from level 1 (minimum) to level 5 (maximum): no problems (1), slight problems (2), moderate problems (3), severe problems (4), and extreme problems (5).

Other Outcome Measures

  1. Association of clinically relevant variations in QoL with disease recurrence and survival [24 months]

    Association of DFS, EFS and OS with clinically relevant variations of EORTC QLQ-C30 and HN43 scales

  2. Correlation of time-dependent variations in QoL with disease-free survival (DFS) [24 months]

    Correlation of DFS with time-dependent clinically relevant variations of EORTC QLQ-C30 and HN43 scales (variations > +10 points or < -10 points in each previously cited questionnaire scale)

  3. Correlation of time-dependent variations in QoL with event-free survival (EFS) [24 months]

    Correlation of EFS with time-dependent clinically relevant variations of EORTC QLQ-C30 and HN43 scales (variations > +10 points or < -10 points in each previously cited questionnaire scale)

  4. Correlation of time-dependent variations in QoL with overall survival (OS) [24 months]

    Correlation of OS with time-dependent clinically relevant variations of EORTC QLQ-C30 and HN43 scales (variations > +10 points or < -10 points in each previously cited questionnaire scale)

  5. Correlation of time-dependent variations in QoL with disease-free survival (DFS) in nasopharyngeal carcinoma [24 months]

    Correlation of DFS with time-dependent clinically relevant variations of EORTC QLQ-C30 and HN43 scales (variations > +10 points or < -10 points in each previously cited questionnaire scale) in nasopharyngeal carcinoma patients

  6. Correlation of time-dependent variations in QoL with event-free survival (EFS) in nasopharyngeal carcinoma [24 months]

    Correlation of EFS with time-dependent clinically relevant variations of EORTC QLQ-C30 and HN43 scales (variations > +10 points or < -10 points in each previously cited questionnaire scale) in nasopharyngeal carcinoma patients

  7. Correlation of time-dependent variations in QoL with overall survival (OS) in nasopharyngeal carcinoma [24 months]

    Correlation of OS with time-dependent clinically relevant variations of EORTC QLQ-C30 and HN43 scales (variations > +10 points or < -10 points in each previously cited questionnaire scale) in nasopharyngeal carcinoma patients

  8. Clinically meaningful deterioration of further pre-specified EORTC-QLQ-HN43 scales QoL between at least 2 visits during post-treatment follow-up [6-24 months]

    Pre-specified HN43 scales non included in secondary endpoints (pain, senses problems, body image, dry mouth, sticky saliva, coughing, trouble social contact, neurological problems, less sexuality, problems with shoulder, skin problems). Score range: 0-100 (higher score = higher level of symptomatology / problems)

  9. Development of predictive models through artificial intelligence techniques [24 months]

    Association of health-related data recorded by the BD4QoL platform registered continuously within the study observation period (Data detected from the mobile device's operating system: Phone usage logs, Phone applications usage; Data from external datasets: steps, identification of places through the correlation of one's GPS signal per day with external datasets from Foursquare and OpenStreet maps) with clinically relevant variations of EORTC QLQ-C30 and HN43 scales (variations > +10 points or < -10 points in each previously cited questionnaire scale)

  10. Correlation of clinically relevant QoL variations with self-efficacy for coping with cancer [24 months]

    Correlation of clinically relevant variations of EORTC QLQ-C30 and HN43 scales (variations > +10 points or < -10 points in each previously cited questionnaire scale) and CBI-B item scores. CBI-B consists of 12 items (rated 1 = not at all confident to 7 = totally confident) and is derived from the longer version of the Cancer Behavior Inventory (CBI). The CBI-B total score can be computed by averaging single item scores through arithmetic mean and, thus, ranges in value from 1 to 7.

  11. Clinically meaningful deterioration of global QoL according to time from treatment completion [24 months]

    Analysis of the primary endpoint stratifying subjects according to timing after study completion (less than 12 months versus more than 12 months)

  12. Economic impact on HNC survivor care and the viability, usability, and trust of using the BD4QoL platform [24 months]

    Incremental Cost-Effectiveness Ratio measured in €/QALY. Measures of viability, usability, and trust

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Effectively cured histologically defined head and neck squamous cell carcinoma (HNSCC) from one of these subsites: oral cavity, nasopharynx, hypopharynx, larynx, Human Papillomavirus (HPV)-positive or negative oropharynx, nasal cavity, paranasal sinuses (ICD codes in Annex 12). Non-metastatic salivary gland cancer (SGC) of any histological type can be included only if curative or postoperative radiotherapy included the neck:

  2. For p16-negative or p16-unknown HNSCC (including nasal cavity and paranasal sinuses), stage I, II, III, IVa or IVb (no IVc) according to UICC/AJCC 8th edition22. Regional neck metastases from squamous cell carcinoma from unknown primary head and neck sites are allowed.

  3. For nasopharyngeal cancer (NPC), stage I, II, III, IVa (no IVb) according to UICC/AJCC 8th edition22. Regional neck metastases from EBV-positive carcinoma from unknown primary head and neck sites are allowed.

  4. For SGCs, stage III, IVa or IVb according to UICC/AJCC 8th edition22 treated with radiotherapy that included the neck (either post-operative radiation or radical treatment in case of unresectable disease).

  5. For p16-positive oropharyngeal squamous cell carcinoma, stage I, II or III according to UICC/AJCC 8th edition22. Regional neck metastases from p16-positive and/or HPV-positive squamous cell carcinoma from unknown primary head and neck sites are allowed.

  6. Patients having completed treatment with curative intent (including any single modality or multimodal approach) within 10 years at the time of accrual.

  7. Patients being disease-free at the time of accrual. Patients will be deemed in complete remission if the clinical examination is negative for recurrence; clinical examination should be preferably, but not mandatorily, integrated with unequivocal radiological imaging that shows the absence of disease (in case of doubt, further radiological imaging should be performed or integrated with cyto/histological samples of the area with suspected disease persistence and the exams will have to be consistently negative) after at least three months following treatment completion.

  8. Ability to fill in questionnaires as per protocol.

  9. Geographical accessibility and willingness to be followed-up for up to 2 years with information-technology (IT) devices in addition to questionnaires.

  10. Age ≥ 18 years.

  11. Signed informed consent.

  12. Willingness to use their smartphone and their Internet access for the study.

  13. Smartphone having the following minimum characteristics:

  14. RAM: Minimum of 2 GB

  15. Storage: Minimum of 512 MB free storage

  16. Operating system: Android version 7 (Nougat) or upper.

Exclusion Criteria:
  1. Distant metastases (the following populations are excluded: stage IVc HPV-negative HNSCC and SGC, stage IV p16-positive oropharyngeal squamous cell carcinoma, stage IVb NPC).

  2. Thyroid cancers, non-melanoma skin cancers (e.g. squamous cell carcinoma of the skin, skin basal cell carcinoma, skin adnexal carcinoma), and non-carcinoma of the head and neck area (e.g. melanoma, sarcoma, etc.) are excluded.

  3. Subjects with previous malignancies (except localized non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, esophageal, endometrial, cervical/dysplasia, melanoma, or breast) unless a complete remission was achieved at least 5 years prior to study entry AND no additional therapy is required during the study period. Premalignant lesions (e.g. leukoplakia, erythroplakia, lichen etc.) are allowed.

  4. Participation in clinical trials with other experimental agents within 30 days of study entry or concomitant treatment with experimental drugs.

  5. Patients unable to comply with the protocol, in the opinion of the investigator.

  6. Any known or underlying medical conditions that, in the opinion of the investigator, could adversely affect the ability of the participating subject to comply with the study.

  7. Having a smartphone operating system other than Android.

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1Fondazione IRCCS Istituto Nazionale dei TumoriMilanoItaly
2Fondazione Casa Sollievo della SofferenzaSan Giovanni RotondoItaly
3University Hospitals Birmingham NHS Foundation TrustBirminghamUnited Kingdom

Sponsors and Collaborators

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
  • Fondazione Casa Sollievo della Sofferenza
  • University Hospital Birmingham NHS Foundation Trust
  • Dotsoft Olokliromenes Efarmoges Diadiktioy kai Vaseon Dedomenon AE
  • IBM Ireland limited
  • INETUM
  • Multimed Engineers srl
  • Regione Lombardia
  • Universidad de la Iglesia de Deusto Entidad Religiosa
  • Universidad Politecnica de Madrid
  • University of Milan
  • Universitetet i Oslo
  • Johannes Gutenberg University Mainz
  • Aria S.p.A.
  • University of Bristol

Investigators

  • Principal Investigator: Carlo Resteghini, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
  • Principal Investigator: Alfonso Manfuso, MD, Fondazione Casa Sollievo della Sofferenza
  • Principal Investigator: Hisham Mehanna, MD, Prof, University Hospital Birmingham NHS Foundation Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
ClinicalTrials.gov Identifier:
NCT05315570
Other Study ID Numbers:
  • INT 267-21
First Posted:
Apr 7, 2022
Last Update Posted:
Apr 7, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 7, 2022